Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT03750825 |
Other study ID # |
HS-18-00744 |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
December 1, 2021 |
Est. completion date |
June 30, 2024 |
Study information
Verified date |
April 2023 |
Source |
University of Southern California |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
This project will address a growing public health concern, namely, the health risks or
benefits of e-cig use relative to cigarette smoking. The investigators will use biomarkers of
early effects of relevance to cancer to determine the carcinogenic potential of e-cig use
relative to cigarette smoking in oral epithelium, which is a target tissue for
smoking-associated cancer. The study population will consist of one group of smokers who are
interested in switching to e-cig use (Grp 1), one group of smokers who do not intend to
change their smoking habits (Grp 2), and one group of non-users who would like to maintain
their nonsmoking non-vaping status (Grp 3); The total number of participants in this project
is 150 (n = 50, each group). The investigators will use an integrative 'multi-omics' approach
complemented with single-locus/gene validation analyses to detect temporal changes in the
genome, epigenome, and transcriptome relevant to cancer in the oral cells of the participants
as the intervention progresses.
Description:
Electronic cigarettes (e-cig) are increasingly popular among adult smokers and adolescent
never smokers. Chemical analyses of e-cig vapor and liquid have shown the presence of many of
the same carcinogens as those found in cigarette smoke, albeit in generally lower
concentrations. However, the carcinogenic potential of e-cig has not been investigated in
e-cig users (otherwise known as 'vapers'). The investigators will investigate the
cancer-causing potential of e-cig use as compared to cigarette smoking by quantifying
molecular changes linked to risk of cancer in smokers who switch to e-cig use vs. those who
maintain their smoking habits. Leveraging a source population for ongoing studies on e-cig,
the investigators will recruit smokers who are interested in switching to e-cig use, and two
control groups of non-vapers, including smokers and nonsmokers who do not intend to change
their smoking and nonsmoking status, respectively (n = 50, each group). Smokers consenting to
switch completely to e-cig will be assigned to a 3-month intervention with a standard e-cig
with fully described product characteristics. Control groups will maintain their
smoking/nonsmoking habits during the intervention. At weekly intervals, the investigators
will verify participants' compliance through personal interviews, CO breath tests, cotinine
quantification, and vaping/smoking topography measurements. The investigators will use a
non-invasive brushing technique to collect oral cells from the inside of the cheeks of all
participants at baseline and every 2 weeks, afterwards. The investigators will use an
integrative 'multi-omics' approach complemented with single-locus/gene validation analyses to
detect temporal changes in the genome, epigenome, and transcriptome relevant to cancer in the
oral cells of the participants as the intervention progresses.